NUVB vs NXTC

Nuvation Bio Inc. vs NextCure, Inc. — Valuation Comparison 2026

NUVB

Biotechnology
Nuvation Bio Inc.
Quality
5.4
out of 10
Value Trap
30
LOW
Price
$4.75
Last close
Models
11/13
Active
VS

NXTC

Biotechnology
NextCure, Inc.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$6.40
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType NUVB Fair ValueNUVB Upside NXTC Fair ValueNXTC Upside
Bayesian DCF Intrinsic $1.26 -73.5% $3.41 -46.7%
Earnings Power Value Intrinsic $0.23 -94.9%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.07 -98.5% $18.39 +187.4%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NUVB vs NXTC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NUVB vs NXTC — Which Stock Is More Undervalued?

NUVB scores higher with a 5.4/10 quality rating vs NXTC's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nuvation Bio Inc. (NUVB) and NextCure, Inc. (NXTC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NUVB currently trades at $4.75 with a QOC of 5.4/10, while NXTC trades at $6.40 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).